Literature DB >> 24638120

Profiting and providing less care: comprehensive services at for-profit, nonprofit, and public opioid treatment programs in the United States.

Marcus A Bachhuber1, William N Southern, Chinazo O Cunningham.   

Abstract

BACKGROUND: Opioid use disorders are frequently associated with medical and psychiatric comorbidities (eg, HIV infection and depression), as well as social problems (eg, lack of health insurance). Comprehensive services addressing these conditions improve outcomes.
OBJECTIVE: To compare the proportion of for-profit, nonprofit, and public opioid treatment programs offering comprehensive services, which are not mandated by government regulations. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional analysis of opioid treatment programs offering outpatient care in the United States (n=1036). MAIN OUTCOME MEASURE: Self-reported offering of communicable disease (HIV, sexually transmitted infections, and viral hepatitis) testing, psychiatric services (screening, assessment and diagnostic evaluation, and pharmacotherapy), and social services support (assistance in applying for programs such as Medicaid). Mixed-effects logistic regression models were developed to adjust for several county-level factors.
RESULTS: Of opioid treatment programs, 58.0% were for profit, 33.5% were nonprofit, and 8.5% were public. Nonprofit programs were more likely than for-profit programs to offer testing for all communicable diseases [adjusted odds ratios (AOR), 1.7; 95% confidence interval (CI), 1.2, 2.5], all psychiatric services (AOR, 8.0; 95% CI, 4.9, 13.1), and social services support (AOR, 3.3; 95% CI, 2.3, 4.8). Public programs were also more likely than for-profit programs to offer communicable disease testing (AOR, 6.4; 95% CI, 3.5, 11.7), all psychiatric services (AOR, 25.8; 95% CI, 12.6, 52.5), and social services support (AOR, 2.4; 95% CI, 1.4, 4.3).
CONCLUSIONS: For-profit programs were significantly less likely than nonprofit and public programs to offer comprehensive services. Interventions to increase the offering of comprehensive services are needed, particularly among for-profit programs.

Entities:  

Mesh:

Year:  2014        PMID: 24638120      PMCID: PMC4277871          DOI: 10.1097/MLR.0000000000000121

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  34 in total

1.  Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs.

Authors:  Gary Marks; Nicole Crepaz; J Walton Senterfitt; Robert S Janssen
Journal:  J Acquir Immune Defic Syndr       Date:  2005-08-01       Impact factor: 3.731

2.  Psychotherapy in community methadone programs: a validation study.

Authors:  G E Woody; A T McLellan; L Luborsky; C P O'Brien
Journal:  Am J Psychiatry       Date:  1995-09       Impact factor: 18.112

3.  Pretreatment source of income and response to methadone maintenance: a follow-up study.

Authors:  A T McLellan; J C Ball; L Rosen; C P O'Brien
Journal:  Am J Psychiatry       Date:  1981-06       Impact factor: 18.112

4.  The functioning and well-being of patients with unrecognized anxiety disorders and major depressive disorder.

Authors:  W H Schonfeld; C J Verboncoeur; S K Fifer; R C Lipschutz; D P Lubeck; D P Buesching
Journal:  J Affect Disord       Date:  1997-04       Impact factor: 4.839

5.  Smoking cessation services in U.S. methadone maintenance facilities.

Authors:  Kimber P Richter; Won S Choi; Robert M McCool; Kari J Harris; Jasjit S Ahluwalia
Journal:  Psychiatr Serv       Date:  2004-11       Impact factor: 3.084

6.  Psychiatric and substance use comorbidity among treatment-seeking opioid abusers.

Authors:  R K Brooner; V L King; M Kidorf; C W Schmidt; G E Bigelow
Journal:  Arch Gen Psychiatry       Date:  1997-01

7.  Providing medical care to methadone clinic patients: referral vs on-site care.

Authors:  A Umbricht-Schneiter; D H Ginn; K M Pabst; G E Bigelow
Journal:  Am J Public Health       Date:  1994-02       Impact factor: 9.308

Review 8.  Evidence for the effects of HIV antibody counseling and testing on risk behaviors.

Authors:  D L Higgins; C Galavotti; K R O'Reilly; D J Schnell; M Moore; D L Rugg; R Johnson
Journal:  JAMA       Date:  1991-11-06       Impact factor: 56.272

9.  Psychiatric comorbidity in methadone maintained patients.

Authors:  B J Mason; J H Kocsis; D Melia; E T Khuri; J Sweeney; A Wells; L Borg; R B Millman; M J Kreek
Journal:  J Addict Dis       Date:  1998

10.  Insights from a national survey into why substance abuse treatment units add prevention and outreach services.

Authors:  Rebecca Wells; Christy Harris Lemak; Thomas A D'Aunno
Journal:  Subst Abuse Treat Prev Policy       Date:  2006-08-03
View more
  4 in total

1.  Medicaid Coverage of Methadone Maintenance and the Use of Opioid Agonist Therapy Among Pregnant Women in Specialty Treatment.

Authors:  Marcus A Bachhuber; Pooja K Mehta; Laura J Faherty; Brendan Saloner
Journal:  Med Care       Date:  2017-12       Impact factor: 2.983

2.  Quality of primary care among individuals receiving treatment for opioid use disorder.

Authors:  Sheryl Spithoff; Tara Kiran; Wayne Khuu; Meldon Kahan; Qi Guan; Mina Tadrous; Pamela Leece; Diana Martins; Tara Gomes
Journal:  Can Fam Physician       Date:  2019-05       Impact factor: 3.275

3.  Association Between Interorganizational Collaboration in Opioid Response and Treatment Capacity for Opioid Use Disorder in Counties of Five States: A Cross-Sectional Study.

Authors:  William L Swann; Michael DiNardi; Terri L Schreiber
Journal:  Subst Abuse       Date:  2022-07-13

4.  Integrated hepatitis C treatment is associated with improved retention and success in outpatient treatment for opioid use disorder at a private clinic.

Authors:  Phyllis Losikoff; Jordon D Bosse; Stephen A Martin; Amanda Wilson; Lisa M Chiodo
Journal:  Front Psychiatry       Date:  2022-09-14       Impact factor: 5.435

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.